Cancer treatment – how to wisely reduce its burden? A new ESMO tool to guide de-intensification
ESMO developed a classification to assess the risk-benefit ratio of treatment intensity modulation by a three-tiered approach
How to discuss cancer treatment modulation with patients?
Experience in breast cancer shows that treatment de-intensification must follow robust evidence, but also values and preferences to generate acceptance
De-escalation of cancer treatments may be key to sustainability in oncology
Treating patients at reduced doses could contribute to a more efficient allocation of healthcare resources and improve access to costly treatments around the world, but implementation of de-escalation in routine practice requires reliable and cost-effective tools to safely tailor therapy to patients
Featured content
Can academic oncology compete with the career prospects offered by the pharma industry?
Moving back and forth across academic and corporate positions has become increasingly common for oncologists in search of new opportunities
Ukraine: what help for refugees with breast cancer?
In neighbouring countries, oncologists are seeing a growing number of female refugees with breast cancer whose treatment may have started before they left Ukraine and urgently needs to be continued for good outcomes to be achieved.
Rare cancers: research progresses, but policy lags behind
A Call to Action of Rare Cancers Europe encourages policy makers to take greater action to ensure rare cancers are not overlooked from the policy agenda.
The unique needs of LGBTQ cancer patients are still poorly understood
Despite lacking scientific evidence on how to tailor cancer prevention and treatment to this community, three out of four oncologists want to expand their knowledge to better assist LGBTQ patients, as an ESMO-SIOPE survey reveals
Patient sex and gut microbiome play a role in modulating response to immunotherapy
Research is ongoing to investigate influencing factors of immune checkpoint inhibition, encouraging a more holistic understanding of individual characteristics to improve clinical outcomes
Optimising clinical trials for greater inclusiveness
Oncologists are aiming to capitalise on lessons learned from the COVID-19 pandemic and design more inclusive clinical trials, optimise trial endpoints and make better use of real-world evidence.
Cancer care in war zones: what have we learnt?
In recent conflicts, good response to the health needs of refugees with cancer in receiving countries is consequence of an analysis of local cancer centres capacity and special measures to avoid fragmented care
Anti-cancer medicines are typically approved in the USA eight months before Europe
Discrepancies in anti-cancer drug approvals around the globe are even bigger in low- and middle-income countries, raising some questions about how they impact on patients’ access to quality cancer care.